Corporate Program JUNE 13-16, 2021 - ANNUAL CONFERENCE OF CELL THERAPY TRANSPLANT CANADA
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
JUNE 13-16, 2021
Corporate
Program
ANNUAL CONFERENCE OF
CELL THERAPY TRANSPLANT CANADA
CTTC Head Office: 750 West Pender Street, Suite 301, Vancouver, BC, V6C 2T7 • T: 604-874-4944 F: 604-874-4378 E: info@cttcanada.org W: www.cvttcanada.org
Jazz Pharmaceuticals is a global biopharmaceutical company
whose purpose is to transform the lives of patients
• We are focused on developing life-changing medications for people with serious
diseases – often with limited or no options – so they can live their lives more fully
• Jazz has a growing hematology and oncology therapeutic area – with a focus in the
areas of relapsed small cell lung cancer, acute leukemias, both lymphocytic and myeloid,
and for patients who develop an ultra-rare complication of hematopoietic stem cell
transplantation known as veno-occlusive disease
• Through continued investment in research and development, we seek solutions
for rare or complex diseases, ensuring those solutions are available for the
often-overlooked patients who need them most
Visit www.jazzpharma.com to learn more about what Jazz Pharmaceuticals has to offer
©2021 Jazz Pharmaceuticals, Inc. All rights reserved.
Corporate Program
JUNE 13-16, 2021
SPONSOR LISTING
We would like to thank the sponsors of the Cell Therapy Transplant Canada 2021 Annual Meeting. This conference is made possible through
the generous support of the following companies:
PLATINUM SPONSOR
GOLD SPONSORS
SILVER SPONSOR BRONZE SPONSORS
CONFERENCE SUPPORTERS CONFERENCE CONTRIBUTORS
CONFERENCE EXHIBITORS
AVIR Pharma Inc. | Apobiologix | Bristol Myers Squibb | Janssen Inc. | Jazz Pharmaceuticals | Kite, a Gilead Company | Merck Canada |
Miltenyi Biotec | Novartis | Pfizer Canada | Sanofi | Seagen Canada | Taiho Pharma
ANNUAL CONFERENCE OF CELL THERAPY TRANSPLANT CANADA 3
CTTC Head Office: 750 West Pender Street, Suite 301, Vancouver, BC, V6C 2T7 • T: 604-874-4944 F: 604-874-4378 E: info@cttcanada.org W: www.cttcanada.org
Corporate Program
JUNE 13-16, 2021
CORPORATE PROGRAM
DAY 1: JUNE 14, 2021
LUNCH SYMPOSIUM
1:15pm – 2:15pm Eastern Time
FROM BED SCALE TO DEFIBROTIDE: MULTI-DISCIPLINARY APPROACH TO THE
MANAGEMENT OF SINOSUIDAL OBSTRUCTION SYNDROME (SOS)/VENO-OCCLUSIVE
DISEASE (VOD)
DINNER SYMPOSIUM
6:30pm – 7:30pm Eastern Time
NOVEL THERAPIES IN AML—HOW TO TAILOR TREATMENT IN THE EVOLVING
LANDSCAPE
DAY 2: JUNE 15, 2021
BREAKFAST SYMPOSIUM
9:00am – 10:00am Eastern Time
CAR-T CELL THERAPY FOR DIFFUSE LARGE B-CELL LYMPHOMA IN 2021
DAY 3: JUNE 16, 2021
LUNCH SYMPOSIUM
1:15pm – 2:15pm Eastern Time
EVOLVING TREATMENT PARADIGMS FOR NEWLY DIAGNOSED PATIENTS WITH
MULTIPLE MYELOMA: THE ROLE OF TRANSPLANT VS. NOVEL AGENTS
ANNUAL CONFERENCE OF CELL THERAPY TRANSPLANT CANADA 4
CTTC Head Office: 750 West Pender Street, Suite 301, Vancouver, BC, V6C 2T7 • T: 604-874-4944 F: 604-874-4378 E: info@cttcanada.org W: www.cttcanada.org
Corporate Program
JUNE 13-16, 2021
SPONSORED SYMPOSIA DESCRIPTIONS
DAY 1: JUNE 14, 2021
LUNCH SYMPOSIUM
1:15pm – 2:15pm Eastern Time
FROM BED SCALE TO DEFIBROTIDE: MULTI-DISCIPLINARY APPROACH TO THE MANAGEMENT OF SINOSUIDAL
OBSTRUCTION SYNDROME (SOS)/VENO-OCCLUSIVE DISEASE (VOD)
Speakers:
Dr. Ivan Pasic, Hans Messner Allogeneic Transplant Program, Princess Margaret Hospital, Ontario
Susan Clarke, Nurse Manager, Hans Messner Allogeneic Transplant Program, Princess Margaret Hospital, Ontario
Zoe Evans, Hans Messner Allogeneic Transplant Program, Princess Margaret Hospital
Ian Pang, Clinical Pharmacist, Hans Messner Allogeneic Transplant Program, Princess Margaret Hospital, Ontario
Synopsis: In this interactive roundtable discussion attendees will have an opportunity to review the current evidence-based multi-disciplinary
approach to sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD), a common complication of allogeneic hematopoietic cell
transplantation caused by injury to the sinusoidal system endothelium and characterized by progressive and sometimes fatal multi-organ
dysfunction. The speakers on the panel are members of the Hans Messner Allogeneic Transplant Program at Princess Margaret Hospital,
Toronto, and include a staff physician, nurse manager, nurse practitioner and clinical pharmacist in the program. The speakers will review
such topics as pathophysiology of SOS/VOD, recognition of its signs and symptoms and will review other diagnoses which can often be
confused with SOS/VOD. Attention will be given to the revised diagnostic and severity criteria for SOS/VOD with an emphasis on their utility
in the decision-making regarding the choice of most appropriate therapy for SOS/VOD. Attention will be given to the unique roles played by
the different care team members in the management of transplant patients with SOS/VOD.
Learning Objectives:
At the end of the session, the attendee will be able to:
• Describe the pathophysiology of SOS/VOD, recognize signs and symptoms of SOS/VOD, list differential diagnoses of SOS/VOD and
discuss the evidence behind therapeutic modalities for SOS/VOD.
• Discuss and apply the revised diagnostic and severity criteria for SOS/VOD in decision-making regarding the choice of most
appropriate therapy for SOS/VOD.
• Day-to-day multi-disciplinary approach to the management on patients with SOS/VOD on allogeneic stem cell transplant inpatient
units.
ANNUAL CONFERENCE OF CELL THERAPY TRANSPLANT CANADA 5
CTTC Head Office: 750 West Pender Street, Suite 301, Vancouver, BC, V6C 2T7 • T: 604-874-4944 F: 604-874-4378 E: info@cttcanada.org W: www.cttcanada.org
Corporate Program
JUNE 13-16, 2021
DAY 1: JUNE 14, 2021
DINNER SYMPOSIUM
6:30pm – 7:30pm Eastern Time
NOVEL THERAPIES IN AML—HOW TO TAILOR TREATMENT IN THE EVOLVING LANDSCAPE
Speaker:
Dr. Eunice Wang, Roswell Park Comprehensive Cancer Center, New York
Dr. Brian Leber, McMaster University, Ontario (moderator)
Synopsis: Since 2017, multiple new agents have been approved for the treatment of acute myeloid leukemia (AML). Harnessing the potential
of these drugs, however, can be challenging for the practicing clinician. This talk will review the mechanisms of actions and unique side
effects of novel therapies. Case presentations will highlight challenging scenarios and the decision-making process for individual patients.
Learning Objectives:
• Provide an overview of the current and evolving treatment landscape for AML and provide framework for clinical treatment decision-
making
• Accelerate learning for practical management of patients undergoing intensive treatments
• Discuss challenging AML cases and clinical evidence supporting treatment choices
DAY 2: JUNE 15, 2021
BREAKFAST SYMPOSIUM
9:00am – 10:00am Eastern Time
CAR-T CELL THERAPY FOR DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN 2021
Speakers:
Dr. Ran Reshef, Columbia University Irving Medical Center, New York
Dr. Ronan Foley, Juravinski Hospital, Ontario (Moderator)
Synopsis: Dr. Reshef will provide insight on the use of CAR T-cell therapy for DLBCL in 2021. The discussion will explore:
• The unmet need in DBCL today, and the place for CAR T therapy
• Overview of key landmark CAR T trials in DLBCL and emerging real-world evidence
• Patient identification and the importance of timely referrals
• Practical implications as it relates to continuity of care between referring and treating physicians
• Patient management post-CAR T therapy
Learning Objectives:
• Review of the unmet need in DLBCL and the place for CAR T therapy
• Present data from key landmark CAR T trials in DLBCL
• Patient identification and selection, and importance of timely referrals (use of patient cases)
• Practical implications as it relates to the sharing/continuity of care / responsibilities with referring physicians
• Patient Management post CAR T therapy
• Discuss emerging real-world evidence from the use of CAR T therapies in clinical practice
ANNUAL CONFERENCE OF CELL THERAPY TRANSPLANT CANADA 6
CTTC Head Office: 750 West Pender Street, Suite 301, Vancouver, BC, V6C 2T7 • T: 604-874-4944 F: 604-874-4378 E: info@cttcanada.org W: www.cttcanada.org
Corporate Program
JUNE 13-16, 2021
DAY 3: JUNE 16, 2021
LUNCH SYMPOSIUM
1:15pm – 2:15pm Eastern Time
EVOLVING TREATMENT PARADIGMS FOR NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA: THE ROLE OF
TRANSPLANT VS. NOVEL AGENTS
Speakers:
Dr. Joseph Mikhael, Translational Genomics Research Institute, City of Hope Cancer Center, HonorHealth Clinical Research Institute, Arizona
Dr. C. Ola Landgren, Sylvester Comprehensive Cancer Center, University of Miami, Florida
Dr. Richard LeBlanc, Hôpital Maisonneuve-Rosemont, University of Montreal, Québec (Moderator)
Learning Objectives:
• To highlight recent advances in novel induction strategies and their advantages for newly diagnosed patients with Multiple Myeloma
who are deemed appropriate for autologous stem cell transplantation
• To consider how the introduction of novel treatment options for newly diagnosed Multiple Myeloma has improved the outcomes for
older patients who may not be appropriate for autologous stem cell transplantation
• To debate the evolving approach to determining the best treatment for newly diagnosed patients with Multiple Myeloma in order to
achieve deep, durable responses and maximize long-term outcomes
ANNUAL CONFERENCE OF CELL THERAPY TRANSPLANT CANADA 7
CTTC Head Office: 750 West Pender Street, Suite 301, Vancouver, BC, V6C 2T7 • T: 604-874-4944 F: 604-874-4378 E: info@cttcanada.org W: www.cttcanada.org
We’re inspired by a single vision:
Transforming patients’ lives
through science
www.bms.com/ca/en
By putting
lives first, we’ve
created a legacy
that lasts
For nearly 130 years, we have tackled some of the world’s biggest
health challenges and provided hope in the fight against disease,
for both people and animals. Today, we continue our commitment
to be the premier research-intensive biopharmaceutical company
in pursuit of medical breakthroughs that benefit patients and
society for today, tomorrow and generations to come.
Copyright © 2021 Merck Canada Inc. All rights reserved.
Corporate Program
JUNE 13-16, 2021
SPONSOR & EXHIBITOR DESCRIPTIONS
We believe that as a leading biosimilar company, it is our
responsibility to continue bringing additional medicines to patients.
But we can’t do it alone. We work in cooperation with our HCP
partners to enhance patient access, optimize patient care and
ensure sustainability of our healthcare system. Visit our website
www.apobiologix.com to learn more.
AVIR PHARMA INC.
AVIR Pharma’s mission is to bring to market vital specialty medicines
that answer the unmet medical needs of Canadian patients. AVIR’s
specialized areas include GI, anti-infectives and pain management.
Located in Blainville, Quebec, AVIR Pharma Inc. is an affiliate of
the Laboratoire Riva Group, a family owned company with over 40
years of experience in manufacturing, packaging and distribution
BIOCANRX
of generic & OTC products in the Canadian marketplace. Making a
difference in people’s lives is central to our corporate philosophy
BioCanRx is Canada’s Immunotherapy Network. Our vision is to cure
and is at the root of why we advocate, care, partner and innovate.
patients and enhance the quality of life of those living with cancer.
We invest in leading edge immune oncology research translating
world-class technologies from the lab into early phase clinical
trials. BioCanRx provides researchers with access to funding,
expertise, training and manufacturing facilities and is a leader in the
translation, manufacture and adoption of cancer immunotherapies.
APOBIOLOGIX biocanrx.com
Apobiologix®, a division of Apotex Inc., focuses on the
commercialization of biosimilars. The Apobiologix® biosimilar
program is a natural extension of Apotex’ long history of providing
access to high-quality, affordable medicines in Canada and across
the globe. We aspire to transform access to affordable therapies
in oncology and beyond through innovation, development and
partnerships. At Apobiologix®, we believe Invention is not the only BRISTOL MYERS SQUIBB
Innovation; we believe healthcare providers and patients deserve
access to affordable therapies without compromising efficacy, At Bristol Myers Squibb, we work every day to help patients.
quality and safety. Patients are at the center of everything we do. They inspire us.
Apobiologix® is a pioneer and leader in oncology biosimilars in They are the reason we come to work each day. We aspire to be
Canada. Even before Apobiologix launched its first biosimilar, we at the center of a vibrant healthcare ecosystem, where academic
were considered a leader in education and awareness of biosimilars research centers, biotech and biopharma companies all contribute
amongst important stakeholder groups. to continued scientific advancement.
ANNUAL CONFERENCE OF CELL THERAPY TRANSPLANT CANADA 10
CTTC Head Office: 750 West Pender Street, Suite 301, Vancouver, BC, V6C 2T7 • T: 604-874-4944 F: 604-874-4378 E: info@cttcanada.org W: www.cttcanada.orgCorporate Program
JUNE 13-16, 2021
JANSSEN INC. KITE, A GILEAD COMPANY
We are the pharmaceutical companies of Johnson & Johnson. Kite, a Gilead company, is a biopharmaceutical company engaged
We focus on the following areas of medicine: cardiovascular in the development of innovative cancer immunotherapies. The
& metabolism, immunology, infectious diseases & vaccines, company is focused on chimeric antigen receptor and T-cell
neuroscience, oncology, and pulmonary hypertension. receptor engineered cell therapies. For more information on Kite,
please visit www.kitepharma.com.
JAZZ PHARMACEUTICALS
MERCK CANADA
Jazz pharmaceuticals has a growing hematology/oncology portfolio,
robust pipeline and remains committed to hematology/oncology For more than 125 years, Merck, known as MSD outside of the United
with a focus in the areas of acute leukemias, both lymphocytic and States and Canada, has been inventing for life, bringing forward
myeloid (ALL and AML) and for patients who develop an ultra-rare medicines and vaccines for many of the world’s most challenging
complication of hematopoietic stem cell transplantation (HSCT), diseases in pursuit of our mission to save and improve lives. We
known as veno-occlusive disease (VOD). With Jazz’s recent entry demonstrate our commitment to patients and population health
into an exclusive license agreement with PharmaMar for the U.S. by increasing access to health care through far-reaching policies,
commercialization of a treatment for relapsed small cell lung cancer programs and partnerships. Today, Merck continues to be at the
(SCLC), we have continued to expand the depth and breadth of our forefront of research to prevent and treat diseases that threaten
oncology pipeline. people and animals—including cancer, infectious diseases such as
HIV and Ebola, and emerging animal diseases—as we aspire to be the
premier research-intensive biopharmaceutical company in the world.
In Canada, Merck markets a broad range of vaccines, pharmaceutical
and animal health products and is one of the top R&D investors in
Canada, with investments totaling $89 million in 2019 and more than
$1.3 billion since 2000. Based in Kirkland, Québec, Merck employs
approximately 650 people across the country. For more information
about our operations in Canada, visit www.merck.ca and connect
with us on YouTube and Twitter @MerckCanada.
ANNUAL CONFERENCE OF CELL THERAPY TRANSPLANT CANADA 11
CTTC Head Office: 750 West Pender Street, Suite 301, Vancouver, BC, V6C 2T7 • T: 604-874-4944 F: 604-874-4378 E: info@cttcanada.org W: www.cttcanada.orgCorporate Program
JUNE 13-16, 2021
PFIZER CANADA
MILTENYI BIOTEC
Pfizer Canada ULC is the Canadian operation of Pfizer Inc., one of
For 30 years, Miltenyi Biotec has played an important role in the
the world’s leading biopharmaceutical companies. Our diversified
design, development, manufacture, and integration of products that
health care portfolio includes some of the world’s best known
empower the advancement of biomedical research and enable cell
and most prescribed medicines, vaccines and consumer health
and gene therapy. Today, we stand at the forefront of pioneering
products. Every day, Pfizer Canada employees work to bring
clinical research with an emphasis on immunotherapy, tissue regen
therapies to patients that significantly improve patients’ lives. We
eration, and graft engineering. Our validated cell manufacturing
apply science and our global resources to improve the health and
products enable GMP-compliant cell processing and have been
well-being of Canadians at every stage of life. Our commitment
used in more than 50,000 cell therapy procedures. In addition, the
is reflected in everything we do, from our disease awareness
automated CliniMACS® Cell Separation System, in combination with
initiatives to our community partnerships.
high-quality MACS GMP and CryoMACS® products, has been used for
the consistent generation of cellular products that are used in a wide To learn more about Pfizer Canada, visit pfizer.ca or you can follow
range of clinical applications. The CliniMACS System also supports us on Twitter (twitter.com/PfizerCA) or Facebook (facebook.com/
graft engineering by enabling the removal of T-cells, T-cells subsets, Pfizer.Canada).
B-cells, and other unwanted cells from hematopoietic stem cell grafts
to overcome relapse and side effects like graft-versus-host disease.
Different clinical strategies are being evaluated to engineer stem cell
grafts for different purposes based on Miltenyi Biotec cell separation
technologies and clinical grade antibodies for different epitopes.
SANOFI
Focused on developing specialty treatments for debilitating
NOVARTIS diseases that are often difficult to diagnose and treat, providing
hope to patients and their families.
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare
field, is committed to the discovery, development and marketing of
innovative products to improve the well-being of all Canadians. In
2017, the company invested $51 million in research and development
in Canada. Located in Dorval, Quebec, Novartis Pharmaceuticals
Canada Inc. employs approximately 750 people in Canada and is
an affiliate of Novartis AG, which provides innovative healthcare
solutions that address the evolving needs of patients and societies.
For further information, please consult www.novartis.ca.
ANNUAL CONFERENCE OF CELL THERAPY TRANSPLANT CANADA 12
CTTC Head Office: 750 West Pender Street, Suite 301, Vancouver, BC, V6C 2T7 • T: 604-874-4944 F: 604-874-4378 E: info@cttcanada.org W: www.cttcanada.orgCorporate Program
JUNE 13-16, 2021
SEAGEN CANADA THÉCELL
Seagen is a global biotechnology company that discovers, ThéCell is a non-profit provincial network supported by the Fonds
develops, and commercializes medicines for cancer. The company de recherche du Québec – Santé (FRQS). Its mission is dedicated to
has a pipeline of therapies at various stages of preclinical testing, further Cell, Gene and Tissue therapies. ThéCell mobilizes researchers
clinical testing, and development. We are leveraging our expertise and resources for the development of new therapeutic approaches
in antibodies to build a portfolio of proprietary immuno-oncology in regenerative medicine. It aims to accelerate the translation of
agents in clinical trials for hematologic malignancies and solid discoveries stemming from Quebec laboratories toward clinical
tumors. applications and treatments. The network acts as a catalyst to promote
the collaboration between more than 135 researchers, clinicians and
their teams (over 360 students and post-docs and 170 associate
members) involved in key health research areas of cell, tissue and
gene therapy, namely: 1) musculoskeletal and nervous systems; 2)
cardiovascular, pulmonary, renal and digestive systems; 3) skin and
cornea systems; and 4) hematology, oncology and immunology.
Seven infrastructures support the activities of the network including:
TAIHO PHARMA preclinical, ethical, social and legal guidance, economic evaluation
as well as GMP production facilities for cells, genes and tissues used
Taiho Pharma Canada, Inc., a Canadian subsidiary of Taiho in clinical trials. ThéCell plays a central role in Quebec’s regenerative
Pharmaceutical Co., Ltd. (Japan), is located in Oakville, Ontario medicine landscape by strengthening scientific exchanges and
and managed by Taiho Oncology, Taiho’s U.S. R&D and commercial promoting the emergence of new partnerships within Canada and
operations, based in Princeton, New Jersey. Taiho Oncology has internationally.
established world class clinical development and commercial
organizations that work urgently to develop and market innovative http://www.reseauthecell.qc.ca/
cancer treatments in the U.S. and Canada. Taiho Oncology Inc. has
an oral oncology pipeline consisting of both novel antimetabolic
agents and selectively targeted agents. Advanced technology,
dedicated researchers, and state of the art facilities are helping
us to define the way the world treats cancer. It’s our work; it’s our
passion; it’s our legacy.
ANNUAL CONFERENCE OF CELL THERAPY TRANSPLANT CANADA 13
CTTC Head Office: 750 West Pender Street, Suite 301, Vancouver, BC, V6C 2T7 • T: 604-874-4944 F: 604-874-4378 E: info@cttcanada.org W: www.cttcanada.orgCorporate Program
JUNE 13-16, 2021
To become a member of the CTTC please
complete the online membership registration at
www.cttcanada.org or contact:
CTTC Head Office
750 West Pender Street, Suite 301
© 2021 Vancouver, BC, V6C 2T7ANNUAL CONFERENCE OF CELL THERAPY TRANSPLANT CANADA CURE STEMS FROM HERE 14
BECOME A MEMBER
ntisCopyright
Canada © 2021
Inc.
T: 604-874-4944 • E: info@cttcanada .org
served.
sanofi-aventis Canada Inc.
www.cttcanada.org
All rights reserved.
CTTC Head Office: 750 West Pender Street, Suite 301, Vancouver, BC, V6C 2T7 • T: 604-874-4944 F: 604-874-4378 E: info@cttcanada.org W: www.cttcanada.orgWE ARE ALWAYS HAPPY TO ASSIST YOU. www.onboard-courier.com Follow us on Linkedin
ABOUT CTTC
The CTTC is a member-led, national, multi-disciplinary
organization providing leadership and promoting excellence in
patient care, research, and education in the field of blood and
marrow transplant.
CTTC’s mission is to be the professional community and voice of
hematopoietic stem cell transplant and cell therapy in Canada. Our vision
is to work together towards world-leading hematopoietic stem cell transplant
and cell therapy for all Canadians.
The CTTC values excellence, innovation, integrity, collaboration, and professionalism
in care, education, and research in hematopoietic stem cell transplant and cell therapy.
The CTTC believes that every patient has a right of equal access to the highest quality of
life saving care that can be provided by hematopoietic stem cell transplant and cell therapy
professionals in Canada.
Based on this, our strategic priorities are as follows:
• Education— Provide high quality educational programs that advance the practice of blood and
marrow transplantation in Canada.
• Quality—Support centers on regulatory matters with standards, guidelines and resources.
• Research—Support research by CTTC members.
• Patients, Families and Caregivers—Support patient led initiatives and activities
• Advocacy—Advocate on behalf of members, programs and patients as needed
• Transparency in Governance—Ensure that all governance and operations are communicated in a transparent
manner to the membership
• Financial Capacity—Support education, research, patient and outreach initiatives through fundraising and
partnerships
CTTC Head Office: 750 West Pender Street, Suite 301, Vancouver, BC, V6C 2T7 • T: 604-874-4944 F: 604-874-4378 E: info@cttcanada.org W: www.cvttcanada.orgYou can also read
